Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Integrated Solutions

Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D.

PROTAC Drug Discovery Research Platform

Medicilon gathers the popular POI ligands and multiple tissue types of E3 ligase ligands, in addition of established a linker library containing hundreds of linking molecules.
Medicilon diamond icon.pngPROTAC technology has a unique mechanism
Medicilon diamond icon.pngAdvantages of PROTAC Technology in Drug Development
Medicilon diamond icon.pngIntroduction of Medicilon PROTAC Services
  • In vitro Screening of PROTAC-POI
    Cytotoxicity Assay (CCK-8 & CTG)
    Mechanism detection by proliferation inhibition tests.

    Percentage-degradation-of-HiBiT-IRAK4-in-HiBiT-IRAK4-overexpression-OCI-LY10-cells.png

    Percentage degradation of HiBiT-IRAK4 in HiBiT-IRAK4 overexpression OCI-LY10 cells

    Western Blot(WB)
    Conduct WB to test target protein degradation ability and analyze DC50.

    Western-blot-of-anti-IRAK4-on-OCI-LY10-cells-treated-with-IRAK4-degrader-1.png

    Western blot of anti-IRAK4 on OCI-LY10 cells treated with IRAK4 degrader-1

    Pomalidomide-(CRBN-binder)-competition-experiment-show-that-IRAK4-degrader-1--degrades-IRAK4-through-CRBN.png

    Pomalidomide (CRBN binder) competition experiment show that IRAK4 degrader-1  degrades IRAK4 through CRBN

    MG132-inhibition-experiment-show-that-IRAK4-degrader-1-degrades-IRAK4-through-proteasome-pathway.png

    MG132 inhibition experiment show that IRAK4 degrader-1 degrades IRAK4 through proteasome pathway

    Tumor cell proliferation inhibition effect test

    Growth-inhibition-effect-of-IRAK4-degrader-1-on-OCI-LY10-cells.png

    Growth inhibition effect of IRAK4 degrader-1 on OCI-LY10 cells

    ACBI1-(BRM-degrader)-degrades-BRM-in-dose-response-manner.png

    ACBI1 (BRM degrader) degrades BRM in dose response manner

  • In Vivo Efficacy Tests of PROTAC-POI
    CDX Mouse Tumor Model

    Cancer TypeOrthotopic ModelOrthotopic Model (Luc Cell Line)
    Brain CancerU87-MGU87-MG-luc
    Lung CancerNCI-H1650, A549, NCI-H1975, NCI-H460, LLC1A549-luc, LLC1-luc,NCI-H1975-luc
    Colon CancerHCT-116, LoVoHT29-luc
    Gastric CancerHs 746T
    Pancreas CancerMia-Paca 2Mia-Paca 2-luc
    Breast CancerMDA-MB-2314T1-luc
    Ovarian CanerSK-OV-3SK-OV-3-luc
    Prostate CancerPC3PC-3-luc
    Renal CancerA498
    Bladder CancerUM-UC-3
    MelanomaB16-F10-luc
    Liver CancerH22
    Bone Cancer
  • In Vivo Efficacy Tests of PROTAC-POI
    PDX Mouse Tumor Model

    Cancer TypeCell Lines
    Colon Cancer                                PDXM-008C, PDXM-016C, PDXM-020C, PDXM-021C, PDXM-057C, PDXM-060C,    PDXM-075C, PDXM-076C, PDXM-087C, PDXM-104C, PDXM-095C, PDXM-084C, PDXM-072C,    PDXM-069C, PDXM-057C, PDXM-015C, PDXM-002C,
    Lung Cancer                                PDXM-054Lu, PDXM-050Lu, PDXM-047Lu, PDXM-053Lu, PDXM-028Lu,
    Gastric CancerPDXM-092Ga, PDXM-091Ga,
    Breast CancerPDXM-201B, PDXM-202B, PDX-203B
    Liver CancerPDXM-211Li, PDXM-212Li
    Pancreas CancerPDXM-221Pa, PDXM-222Pa
    Bladder CancerPDXM-231U, PDXM-232U
    LymphomaPDXM-241Ly, PDXM-242Ly
  • Integrated Preclinical Services
    We can further proceed the R&D of the potential PROTAC molecule by facilitating our integrated preclinical services including CMC services, DMPK studies, safety evaluation, etc.
Return